Agreements reached under this partnership
Business Alliances- 1
Exclusive license for development and commercialization in the US, Europe and Latin America
- 2
Following regulatory approval, Italfarmaco will handle sales and distribution in the licensed territories.
- 3
JCRファーマ will continue to manufacture JR-141.
- 4
JCRファーマ will be entitled to receive upfront payments, milestone payments, royalties and consideration for product supply.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The upfront payment under this agreement has already been incorporated into JCRファーマ's consolidated earnings forecasts for the current fiscal year ending March 2027.
| Item | Details |
|---|---|
| Name of alliance partner | Italfarmaco S.p.A. |
| Alliance partner's business activities | Research, development, manufacturing and commercialization of pharmaceuticals. Operations span a wide range of therapeutic areas, including oncology, gynecology, neurology, cardiovascular disease and rare diseases. |
| Alliance partner's location | Milan, Italy |
| Type of alliance | Business Alliances |
| Details of the alliance | Exclusive license for development and commercialization in the US, Europe and Latin America, Following regulatory approval, Italfarmaco will handle sales and distribution in the licensed territories., JCRファーマ will continue to manufacture JR-141., JCRファーマ will be entitled to receive upfront payments, milestone payments, royalties and consideration for product supply. |
| Contract Date | 2 October 2026 |
| Impact on Business Performance | The upfront payment under this agreement has already been incorporated into JCRファーマ's consolidated earnings forecasts for the current fiscal year ending March 2027. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The agreement is intended to combine the two companies' strengths in development and commercialization to deliver the product to patients with Hunter syndrome worldwide and further develop their partnership in rare diseases and genetic disorders.